When a child is unusually pale, tires easily, or fails to thrive during infancy, parents and doctors often begin a long journey toward answers. One rare but critical condition to consider is Diamond Blackfan Anemia. It’s a disorder that disrupts the body’s ability to produce red blood cells. Getting a diagnosis early can make a life-changing difference, yet the path to diagnosis can be complex and emotionally taxing.
The Styrke Foundation is funding research into curing Diamond Blackfan Anemia, and we could use your help. Please consider donating to the Styrke Foundation here and spreading word of our mission.
Diamond Blackfan Anemia is a rare genetic blood disorder that typically becomes apparent within the first year of life. It’s characterized by pure red cell aplasia, meaning the bone marrow doesn’t produce enough red blood cells, which are essential for carrying oxygen throughout the body. This leads to severe anemia and fatigue. This condition is most commonly linked to a mutation in ribosomal protein genes, which impacts how cells grow and replicate.
Parents often notice DBA when a baby appears extremely pale, has difficulty feeding, or seems unusually lethargic. Some children are diagnosed following routine bloodwork that reveals low hemoglobin levels or abnormal red blood cell counts.
Common Diamond Blackfan Anemia symptoms include:
• Pallor (unusual paleness)
• Fatigue or weakness
• Failure to thrive
• Shortness of breath
• Rapid heartbeat
• Delayed growth and development
In some cases, physical anomalies offer another clue. Up to 50% of children with DBA have congenital abnormalities, such as a triphalangeal thumb (a thumb with three bones, resembling a finger), cleft palate, or heart and kidney defects. These can alert pediatricians to consider a rare genetic condition earlier in the diagnostic process.
Doctors use a combination of blood tests, genetic testing, and clinical criteria to diagnose Diamond Blackfan Anemia. A complete blood count often shows severe anemia with very low counts of immature red blood cells, while white blood cells and platelets usually remain normal.
Further testing may include:
• Bone marrow biopsy: Reveals red cell aplasia
• Genetic testing: Identifies mutations in DBA-related genes
• Family history: Evaluates inheritance patterns
A diagnosis of DBA is life-changing but not hopeless. Treatment plans vary by case and age, but common Diamond Blackfan anemia treatments include:
• Corticosteroids to stimulate red blood cell production
• Blood transfusions for cases resistant to steroids
• Bone marrow transplants
Research is ongoing into targeted gene therapies that could correct the underlying mutation in the future: the Styrke Foundation is funding the research that biotech Apriligen is leading to treat RPS19 deficient Diamond Blackfan Anemia.
Many families may be concerned about what life can be like with Diamond Blackfan Anemia and how their children will adapt. They may take to the internet and search “What is Diamond Blackfan Anemia’s life expectancy?” Thanks to advances in care, many individuals with DBA can live into adulthood and beyond, although they may face long-term complications such as iron overload (from transfusions) or increased cancer risk. Regular monitoring and proactive care are critical to managing the condition over time.
And YOUR generosity can play a role in empowering research, improving outcomes and quality of life, and extending life expectancy through supporting research for a cure.